![](https://nthumb.tpgimages.com/mid2_com_img/1339/29427/TOP27562878.jpg)
Patient holding a pre-filled pen of Risankizumab medication. Marketed as Skyrizi, Risankizumab is a humanised monoclonal antibody that binds to interleukin 23A (IL-23A) and blocks the activity of pro-inflammatory cytokines. Risankizumab is used to treat moderate to severe plaque psoriasis and active psoriatic arthritis. It is administered by a subcutaneous injection.
px | px | dpi | = | cm | x | cm | = | MB |
Details
Creative#:
TOP27562878
Source:
達志影像
Authorization Type:
RM
Release Information:
須由TPG 完整授權
Model Release:
Yes
Property Release:
No
Right to Privacy:
No
Same folder images:
Restriction:
Editorial use only